



DOCTOR'S DIGEST®

Delivering In-depth

Practice Solutions

From the Experts

Sept/Oct 2010

www.doctorsdigest.net

Top-tier Communication

The Impact of Effective Communication

How to Build Rapport

Handling Difficult Encounters

Technology and Communication

The Legal Aspect of Communications



Coming Soon! Doctor's Digest Digital Editions.

Pre-register now for your FREE digital subscription on the iPad and Web and receive a FREE 2GB Credit card-sized USB drive. See page 59 for details.

PERMIT NO. 356
MECHANISBURG, PA
PAID
U.S. POSTAGE
PRESORTED STD



HELP SUPPORT HIS CV HEALTH
IN A BIG WAY WITH LIPITOR

**LIPITOR PUTS THE POWER TO HELP CHANGE THE OUTCOME OF CVD
IN YOUR HANDS BY REDUCING THE RISK OF MI AND STROKE**

LIPITOR is the only potent statin that delivers both proven CV outcomes indications in many of your high-risk patients,* and mean LDL-C reductions >50%. Additionally, only LIPITOR has >10 CV outcomes trials,¹ 6 of which have impacted lipid treatment guidelines.²⁻⁶ And ask your sales representatives about the new patient support tools available.

PRESCRIBE LIPITOR FOR THE STRENGTH PROVEN TO REDUCE THE RISK OF CV EVENTS

LIPITOR is indicated as an adjunct to diet to reduce the risk of myocardial infarction (MI), stroke, revascularization procedures, and angina in adult patients with multiple risk factors but without clinically evident coronary heart disease (CHD); to reduce the risk of MI and stroke in patients with type 2 diabetes and without clinically evident CHD, but with multiple risk factors; to reduce the risk of nonfatal MI, fatal and nonfatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adult patients with clinically evident CHD.

LIPITOR, as an adjunct to diet, is also indicated to reduce elevated total-C, LDL-C, apo B, and TG levels; and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia.

Important Safety Information

LIPITOR is contraindicated in patients with active liver disease or unexplained persistent elevations of hepatic transaminases; in women who are or may become pregnant or who are nursing; in patients with hypersensitivity to any component of this medication.

Rare cases of rhabdomyolysis have been reported with LIPITOR and other statins. Tell patients to promptly report muscle pain, tenderness, or weakness. Predisposing factors include advanced age (≥ 65), uncontrolled hypothyroidism, and renal impairment. Patients with a history of renal impairment merit closer monitoring. In cases of myopathy or rhabdomyolysis, therapy should be temporarily withheld or discontinued.

The concomitant use of higher doses of LIPITOR with certain drugs such as cyclosporine and strong CYP3A4 inhibitors (eg, clarithromycin, itraconazole, and HIV protease inhibitors) increases the risk of myopathy/rhabdomyolysis. Lower doses of LIPITOR should be considered. Physicians should carefully

monitor patients for signs or symptoms of myopathy early during therapy and when titrating the dose of either drug.

It is recommended that liver function tests be performed prior to and 12 weeks following both the initiation of therapy and any elevation of dose, and periodically thereafter. If ALT or AST values $>3 \times$ ULN persist, dose reduction or withdrawal is recommended.

In a post hoc analysis of the SPARCL study in patients without CHD who had a stroke or TIA within the preceding 6 months, a higher incidence of hemorrhagic stroke was seen in the LIPITOR 80-mg group compared with placebo (2.3% vs 1.4%). Some baseline characteristics, including hemorrhagic and lacunar stroke on study entry, were associated with a higher incidence of hemorrhagic stroke in the LIPITOR group.

The most commonly reported adverse reactions with LIPITOR in placebo-controlled trials were: nasopharyngitis, arthralgia, diarrhea, pain in extremity, and urinary tract infection.

References: 1. Data on file, Pfizer Inc, New York, NY. 2. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. *J Am Coll Cardiol*. 2006;47(10):2130-2139. 3. Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. *Stroke*. 2008;39(5):1647-1652. 4. Grundy SM, Cleeman J, Bailey Marz CN, et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation*. 2004;110(2):227-239. 5. American Diabetes Association. Standards of medical care in diabetes—2008. *Diabetes Care*. 2009;32(suppl 1):S13-S61. 6. KDIGO. KDIGO clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. *Am J Kidney Dis*. 2007;49(2)(suppl 2):S1-S170.

*Patients with type 2 diabetes and ≥ 1 risk factor, or CHD.

LIPITOR®

(Atorvastatin Calcium) Tablets
Brief Summary of Prescribing Information

CONTRAINDICATIONS: Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels. Hypersensitivity to any component of this medication. **Pregnancy**—Women who are pregnant or may become pregnant, LIPITOR may cause fetal harm when administered to a pregnant woman. Serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essential for fetal development. Atorvastatin is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. There are no adequate and well-controlled studies of LIPITOR use during pregnancy, however in rare reports, congenital anomalies were observed following intrauterine exposure to statins. In rat and rabbit animal reproduction studies, atorvastatin revealed no evidence of teratogenicity. LIPITOR SHOULD BE ADMINISTERED TO WOMEN OF CHILDBEARING AGE ONLY WHEN SUCH PATIENTS ARE HIGHLY UNLIKELY TO CONCEIVE AND HAVE BEEN INFORMED OF THE POTENTIAL HAZARDS. If the patient becomes pregnant while taking this drug, LIPITOR should be discontinued immediately and the patient apprised of the potential hazard to the fetus [see *Use in Specific Populations* in full prescribing information]. **Nursing mothers**—It is not known whether atorvastatin is excreted into human milk; however, a small amount of another drug in this class does pass into breast milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require LIPITOR treatment should not breastfeed their infants [see *Use in Specific Populations* in full prescribing information].

WARNINGS AND PRECAUTIONS: Skeletal Muscle—Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with LIPITOR and with other drugs in this class. A history of renal impairment may be a risk factor for the development of rhabdomyolysis. Such patients merit closer monitoring for skeletal muscle effects. Atorvastatin, like other statins, occasionally causes myopathy, defined as muscle aches or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values >10 times ULN. The concomitant use of higher doses of atorvastatin with certain drugs such as cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and HIV protease inhibitors) increases the risk of myopathy/rhabdomyolysis. Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevation of CPK. Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. LIPITOR therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected. The risk of myopathy during treatment with drugs in this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, erythromycin, clarithromycin, combination of ritonavir plus saquinavir or lopinavir plus ritonavir, niacin, or azole antifungals. Physicians considering combined therapy with LIPITOR and fibric acid derivatives, erythromycin, clarithromycin, a combination of ritonavir plus saquinavir or lopinavir plus ritonavir, immunosuppressive drugs, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. Lower starting and maintenance doses of atorvastatin should be considered when taken concomitantly with the aforementioned drugs [see *Drug Interactions (7)*]. Periodic creatine phosphokinase (CPK) determinations may be considered in such situations, but there is no assurance that such monitoring will prevent the occurrence of severe myopathy. Prescribing recommendations for interacting agents are summarized in Table 1 [see also *Dosage and Administration, Drug Interactions, Clinical Pharmacology* in full prescribing information].

Table 1. Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis

Interacting Agents	Prescribing Recommendations
Cyclosporine	Do not exceed 10 mg atorvastatin daily
Clarithromycin, itraconazole, HIV protease inhibitors (ritonavir plus saquinavir or lopinavir plus ritonavir)	Caution when exceeding doses > 20 mg atorvastatin daily. The lowest dose necessary should be used.

LIPITOR therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis (e.g., severe acute infection, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders, and uncontrolled seizures).

Liver Dysfunction—Statins, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. **Persistent elevations (>3 times the upper limit of normal [ULN] occurring on 2 or more occasions) in serum transaminases occurred in 0.7% of patients who received LIPITOR in clinical trials. The incidence of these abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 10, 20, 40, and 80 mg, respectively.** One patient in clinical trials developed jaundice. Increases in liver function tests (LFT) in other patients were not associated with jaundice or other clinical signs or symptoms. Upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels without sequelae. Eighteen of 30 patients with persistent LFT elevations continued treatment with a reduced dose of LIPITOR. It is recommended that liver function tests be performed prior to and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. Liver enzyme changes generally occur in the first 3 months of treatment with LIPITOR. Patients who develop increased transaminase levels should be monitored until the abnormalities resolve. Should an increase in ALT or AST of >3 times ULN persist, reduction of dose or withdrawal of LIPITOR is recommended. LIPITOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease. Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of LIPITOR [see *Contraindications* in full prescribing information]. **Endocrine Function**—Statins interfere with cholesterol synthesis and theoretically might blunt adrenal and/or gonadal steroid production. Clinical studies have shown that LIPITOR does not reduce basal plasma cortisol concentration or impair adrenal reserve. The effects of statins on male fertility have not been studied in adequate numbers of patients. The effects, if any, on the pituitary-gonadal axis in premenopausal women are unknown. Caution should be exercised if a statin is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spiro lactone, and cimetidine. **CNS Toxicity**—Brain hemorrhage was seen in a female dog treated for 3 months at 120 mg/kg/day. Brain hemorrhage and optic nerve vacuolation were seen in another female dog that was sacrificed in moribund condition after 11 weeks of escalating doses up to 280 mg/kg/day. The 120 mg/kg dose resulted in a systemic exposure approximately 16 times the human plasma area-under-the-curve (AUC, 0-24 hours) based on the maximum human dose of 80 mg/day. A single tonic convulsion was seen in each of 2 male dogs (one treated at 100 mg/kg/day and one at 120 mg/kg/day) in a 2-year study. No CNS lesions have been observed in mice after chronic treatment for up to 2 years at doses up to 400 mg/kg/day or in rats at doses up to 100 mg/kg/day. These doses were 6 to 11 times (mouse) and 8 to 16 times (rat) the human AUC (0-24) based on the maximum recommended human dose of 80 mg/day. CNS vascular lesions, characterized by perivascular hemorrhages, edema, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with other members of this class. A chemically similar drug in this class produced optic nerve degeneration (Walleria degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion at a dose that produced plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose. **Use in Patients with Recent Stroke or TIA**—In a post-hoc analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study where LIPITOR 80 mg vs. placebo was administered in 4731 subjects without CHD who had a stroke or TIA within the preceding 6 months, a higher incidence of hemorrhagic stroke was seen in the LIPITOR 80 mg group compared to placebo (55, 2.3% atorvastatin vs. 33, 1.4% placebo; HR: 1.68, 95% CI: 1.09, 2.59, p=0.0168). The incidence of fatal hemorrhagic stroke was similar across treatment groups (17 vs. 18 for the atorvastatin and placebo groups, respectively). The incidence of nonfatal hemorrhagic stroke was significantly higher in the atorvastatin group (36, 1.6%) as compared to the placebo group (16, 0.7%). Some baseline characteristics, including hemorrhagic and lacunar stroke on study entry, were associated with a higher incidence of hemorrhagic stroke in the atorvastatin group [see *Adverse Reactions* in full prescribing information].

ADVERSE REACTIONS: The following serious adverse reactions are discussed in greater detail in other sections of the label: Rhabdomyolysis and myopathy [see *Warnings and Precautions* in full prescribing information], liver enzyme abnormalities [see *Warnings and Precautions* in full prescribing information]. **Clinical Trial Adverse Experiences**—Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In the LIPITOR placebo-controlled clinical trial database of 16,066 patients (8755 LIPITOR vs. 7311 placebo; age range 10-93 years, 39% women, 91% Caucasians, 3% Blacks, 2% Asians, 4% other) with a median treatment duration of 53 weeks, 9.7% of patients on LIPITOR and 9.5% of the patients on placebo discontinued due to adverse reactions regardless of causality. The five most common adverse reactions in patients treated with LIPITOR that led to treatment discontinuation and occurred at a rate greater than placebo were: myalgia (0.7%), diarrhea (0.5%), nausea (0.4%), alanine aminotransferase increase (0.4%), and hepatic enzyme increase (0.4%). The most commonly reported adverse reactions (incidence ≥ 2% and greater than placebo) regardless of causality, in patients treated with LIPITOR in placebo controlled trials (n=8755) were: nasopharyngitis (8.3%), arthralgia (6.9%), diarrhea (6.8%), pain in extremity (6.0%), and urinary tract infection (5.7%). Table 2 summarizes the frequency of clinical adverse reactions, regardless of causality, reported in ≥ 2% and at a rate greater than placebo in patients treated with LIPITOR (n=8755), from seventeen placebo-controlled trials.

Table 2. Clinical adverse reactions occurring in ≥ 2% of patients treated with any dose of LIPITOR and at an incidence greater than placebo regardless of causality (% of patients)

Adverse Reaction*	Any dose N=8755	10 mg N=3908	20 mg N=188	40 mg N=604	80 mg N=4055	Placebo N=7311
Nasopharyngitis	8.3	12.9	5.3	7.0	4.2	8.2
Arthralgia	6.9	8.9	11.7	10.6	4.3	6.5
Diarrhea	6.8	7.3	6.4	14.1	5.2	6.3
Pain in extremity	6.0	8.5	3.7	9.3	3.1	5.9
Urinary tract infection	5.7	6.9	6.4	8.0	4.1	5.6
Dyspepsia	4.7	5.9	3.2	6.0	3.3	4.3
Nausea	4.0	3.7	3.7	7.1	3.8	3.5
Musculoskeletal pain	3.8	5.2	3.2	5.1	2.3	3.6
Muscle Spasms	3.6	4.6	4.8	5.1	2.4	3.0
Myalgia	3.5	3.6	5.9	8.4	2.7	3.1
Insomnia	3.0	2.8	1.1	5.3	2.8	2.9
Pharyngolaryngeal pain	2.3	3.9	1.6	2.8	0.7	2.1

*Adverse Reaction ≥ 2% in any dose greater than placebo.

Other adverse reactions reported in placebo-controlled studies include: *Body as a whole*: malaise, pyrexia; *Digestive system*: abdominal discomfort, eructation, flatulence, hepatitis, cholestase; *Musculoskeletal system*: musculoskeletal pain, muscle fatigue, neck pain, joint swelling; *Metabolic and nutritional system*: transaminases increase, liver function test abnormal, blood alkaline phosphatase increase, creatine phosphokinase increase, hyperglycemia; *Nervous system*: nightmare; *Respiratory system*: epistaxis; *Skin and appendages*: urticaria; *Special senses*: vision blurred, tinnitus; *Urogenital system*: white blood cells urine positive.

Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)—In ASCOT [see *Clinical Studies in full prescribing information*] involving 10,305 participants (age range 40–80 years, 19% women; 94.6% Caucasians, 2.6% Africans, 1.5% South Asians, 1.3% mixed/other) treated with LIPITOR 10 mg daily (n=5168) or placebo (n=5137), the safety and tolerability profile of the group treated with LIPITOR was comparable to that of the group treated with placebo during a median of 3.3 years of follow-up.

Collaborative Atorvastatin Diabetes Study (CARDS)—In CARDS [see *Clinical Studies in full prescribing information*] involving 2838 subjects (age range 39–77 years, 32% women; 94.3% Caucasians, 2.4% South Asians, 2.3% Afro-Caribbean, 1.0% other) with type 2 diabetes treated with LIPITOR 10 mg daily (n=1428) or placebo (n=1410), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 3.9 years. No cases of rhabdomyolysis were reported.

Treating to New Targets Study (TNT)—In TNT [see *Clinical Studies in full prescribing information*] involving 10,001 subjects (age range 29–78 years, 19% women; 94.1% Caucasians, 2.9% Blacks, 1.0% Asians, 2.0% other) with clinically evident CHD treated with LIPITOR 10 mg daily (n=5006) or LIPITOR 80 mg daily (n=4995), there were more serious adverse reactions and discontinuations due to adverse reactions in the high-dose atorvastatin group (92, 1.8%; 497, 3.9%, respectively) as compared to the low-dose group (69, 1.4%; 404, 3.1%, respectively) during a median follow-up of 4.9 years. Persistent transaminase elevations (≥ 3 x ULN twice within 4–10 days) occurred in 62 (1.3%) individuals with atorvastatin 80 mg and in nine (0.2%) individuals with atorvastatin 10 mg. Elevations of CK (≥ 10 x ULN) were low overall, but were higher in the high-dose atorvastatin treatment group (13, 0.3%) compared to the low-dose atorvastatin group (6, 0.1%).

Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study (IDEAL)—In IDEAL [see *Clinical Studies in full prescribing information*] involving 8888 subjects (age range 26–80 years, 19% women; 98.3% Caucasians, 0.4% Asians, 0.3% Blacks, 0.04% other) treated with LIPITOR 80 mg/day (n=4439) or simvastatin 20–40 mg daily (n=4449), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 4.8 years.

Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)—In SPARCL involving 4731 subjects (age range 21–92 years, 40% women; 93.3% Caucasians, 3.0% Blacks, 0.6% Asians, 3.1% other) without clinically evident CHD but with a stroke or transient ischemic attack (TIA) within the previous 6 months treated with LIPITOR 80 mg (n=2365) or placebo (n=2366) for a median follow-up of 4.9 years, there was a higher incidence of persistent hepatic transaminase elevations (≥ 3 x ULN twice within 4–10 days) in the atorvastatin group (0.9%) compared to placebo (0.1%). Elevations of CK (>10 x ULN) were rare, but were higher in the atorvastatin group (0.1%) compared to placebo (0.0%). Diabetes was reported as an adverse reaction in 144 subjects (6.1%) in the atorvastatin group and 89 subjects (3.8%) in the placebo group [see *Warnings and Precautions in full prescribing information*].

In a post-hoc analysis, LIPITOR 80 mg reduced the incidence of ischemic stroke (218/2365, 9.2% vs. 274/2366, 11.6%) and increased the incidence of hemorrhagic stroke (55/2365, 2.3% vs. 33/2366, 1.4%) compared to placebo. The incidence of fatal hemorrhagic stroke was similar between groups (17 LIPITOR vs. 16 placebo). The incidence of non-fatal hemorrhagic strokes was significantly greater in the atorvastatin group (38 non-fatal hemorrhagic strokes) as compared to the placebo group (16 non-fatal hemorrhagic strokes). Subjects who entered the study with a hemorrhagic stroke appeared to be at increased risk for hemorrhagic stroke (7 (16%) LIPITOR vs. 2 (4%) placebo).

There were no significant differences between the treatment groups for all-cause mortality; 216 (9.1%) in the LIPITOR 80 mg/day group vs. 211 (8.9%) in the placebo group. The proportions of subjects who experienced cardiovascular death were numerically smaller in the LIPITOR 80 mg group (3.3%) than in the placebo group (4.1%). The proportions of subjects who experienced noncardiovascular death were numerically larger in the LIPITOR 80 mg group (5.0%) than in the placebo group (4.0%).

Postmarketing Experience—The following adverse reactions have been identified during postapproval use of LIPITOR. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Adverse reactions associated with LIPITOR therapy reported since market introduction, that are not listed above, regardless of causality assessment, include the following: anaphylaxis, angioneurotic edema, bullous rashes (including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis), rhabdomyolysis, fatigue, tendon rupture, hepatic failure, dizziness, memory impairment, depression, and peripheral neuropathy.

Pediatric Patients (ages 10–17 years)—In a 26-week controlled study in boys and postmenarcheal girls (n=140, 31% female; 92% Caucasians, 1.6% Blacks, 1.6% Asians, 4.8% other), the safety and tolerability profile of LIPITOR 10 to 20 mg daily was generally similar to that of placebo [see *Clinical Studies in full prescribing information and Use in Special Populations, Pediatric Use in full prescribing information*].

OVERDOSAGE: There is no specific treatment for LIPITOR overdosage. In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as required. Due to extensive drug binding to plasma proteins, hemodialysis is not expected to significantly enhance LIPITOR clearance.

Please see full prescribing information for additional information about LIPITOR.

Rx only

Distributed by:



Parke-Davis

Division of Pfizer Inc, NY, NY 10017

Manufactured by:
Pfizer Ireland Pharmaceuticals
Dublin, Ireland
Rev. 7 August 2009

DOCTOR'S DIGEST

Top-tier Communication

By Laura Gater

ABOUT THE AUTHOR

Laura Gater is a freelance writer specializing in healthcare. Based in Indiana, she has written for such publications as *For the Record*, *Healthcare Traveler*, *Directions in Nursing*, *Podiatry Management*, *Bottom Line/Women's Health*, *HealthMonitor*, and *Corrections Forum*. This is her third book for *Doctor's Digest*.

ADVISORY BOARD

Ellen J. Belzer, MPA, President, Belzer Seminars & Consulting, LLC,
Kansas City, Mo.

Ronald M. Epstein, MD, Professor, Family Medicine, Psychiatry, and Oncology;
Director, Rochester Center to Improve Communication in Health Care,
University of Rochester Medical Center, Rochester, N.Y.

Steven I. Kern, Esq., Principal, Kern Augustine Conroy & Schoppmann, P.C.,
Bridgewater, N.J.

Daniel Levy, MD, Owings Mills, Md., Past President, Maryland Chapter of the
American Academy of Pediatrics

Fred Ralston, Jr., MD, FACP, Fayetteville Medical Associates, Fayetteville, Tenn.,
President, American College of Physicians

Craig M. Wax, DO, Family Physician, Mullica Hill, N.J.

EDITOR Paula S. Katz

SENIOR EDITOR Frank Murphy, Ph.D.

CODING EDITOR Patricia A. Hubbard, CPC

CREATIVE DIRECTOR Gary DeFazio

PRODUCTION DIRECTOR Jane Pickering

PUBLISHER Jeannette Brandofino

MARKETING DIRECTOR Linda Zani Thomas

MARKETING MANAGER Lisa Shevrin

INTELLECTUAL PROPERTY COUNSEL Janet G. Ricciuti, Esq.

The content of *Top-tier Communication*, including such material as text, graphics, images, and other material contained in *Doctor's Digest*, is for informational purposes only. The content is not intended to be a substitute for professional advice. Always seek the advice of professionals with any question you may have. Reliance is at your own risk.

The content of *Top-tier Communication* is protected by copyright under both United States and foreign laws and under United States trademark laws. Title to the content remains with Brandofino Communications, Inc. Any use of the content not expressly authorized by Brandofino Communications, Inc., is a breach of copyright and trademark law. All rights not expressly granted are reserved to Brandofino Communications, Inc.

Doctor's Digest (ISSN 1554-6195), September/October, Volume 6, Number 5. Published bimonthly by Brandofino Communications, Inc., 12 Spruce Park, Syosset, NY 11791. For general subscription information and paid subscriptions, e-mail: doctorsdigest@verizon.net. *Doctor's Digest* is available on a paid subscription basis at the following annual rate: \$54 (foreign, \$108). Single-copy price: \$12. To order, send check or money order payment to *Doctor's Digest*, 12 Spruce Park, Syosset, NY 11791, Attn: Circulation Department (be sure to indicate title of issue, shipping address, and phone number). Visit our Website at www.doctorsdigest.net. For Advertising Sales and Editorial call 516-364-2575 or e-mail doctorsdigest@verizon.net. Postage paid at Mechanicsburg, PA 17055.

Copyright ©2010 and published by Brandofino Communications, Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means electronic or mechanical, including photocopy, recording,

or any information-retrieval system, without permission in writing from the publisher.

Doctor's Digest™ and the split-diagonal, two-toned publication cover are trademarks of Brandofino Communications, Inc.

BRANDOFINO COMMUNICATIONS ■ INC.



Dear Doctor:

Hving pains in mi chst.wat shud i do???.

The very thought of receiving a message like this one is what makes many physicians apprehensive about texting or e-mailing their patients. Yet using technology to enhance physician-patient communication may be inevitable, experts say. This issue of *Doctor's Digest* addresses these concerns and provides a detailed, cutting-edge discussion of effective and appropriate communication skills.



Author Laura Gater explains why communication is a hot topic (think health reform) and discusses its connection to patient adherence and improved outcomes.

She shows why physicians, even those who know better, still lapse into bad habits

and why barriers to good communication persist despite heightened awareness. She then gives a basics refresher, from active listening skills to appropriate response techniques. She tackles the difficult patient encounter—from coping with angry patients to delivering bad news—and offers practical tips on how to best handle these situations. She next discusses how technology impacts communication, exploring how to use e-mail and e-visits and avoid pitfalls. Finally, Laura addresses the legal aspect of communicating with your patients, exploring the risks and offering practical tips on how to avoid legal headaches.

On-the-go technology seems here to stay. We want to hear your opinion of e-readers for electronic medical records and e-prescribing as well as your personal use. Are you currently using them or do you plan to? Why or why not? Let us know by e-mailing your response to doctorsdigest.lisa.shevrin@verizon.net.

I remain dedicated to helping you bridge the gap between the practice of medicine and the business of medicine. As always, I look forward to hearing from you. Contact me at jbrandofino@doctorsdigest.net or by fax to 516-364-2575.

Jeannette

Jeannette Brandofino
Publisher

e-mail: jbrandofino@doctorsdigest.net



**NO ONE GOES THROUGH
MEDICAL SCHOOL
TO PRACTICE INSURANCE.**

Remember graduating from college and passing your MCATs, then spending the next four years of your life getting through classes like clinical epidemiology, neurology and radiology so you could practice medicine? Today's financially driven managed care environments make having a practice difficult. Hurrying patients in and out of the office to make a quota and going into negotiations to prescribe treatments that don't coincide with a patient's policy aren't practicing medicine. We'd like to prescribe a solution: Move your profession to the United States Air Force. Get back to what's important — practicing medicine.



AIRFORCE.COM

Top-tier Communication

Now is the time to review and update your communication skills. If you haven't revisited this topic in a while, you may be missing crucial information about how to incorporate new technology into your interaction with patients along with a fresh look at ways to make the most of your ever-shrinking time with patients.

This issue of *Doctor's Digest* begins by examining why top communication techniques are more important now than ever and what you can gain by making the time to put these into daily practice. Author Laura Gater discusses active listening and knowing how to respond so that your patients will benefit; she also gives tips for communicating with patients with low literacy levels. Next, Laura confronts what can be the hardest communications—talking to angry patients and delivering bad news. She gives you insight and specifics into how to shift a physician-patient relationship from conflict to collaboration. Then Laura shows you why e-mail and e-visits may improve your communication with patients—and how to handle the downsides such as unclear reimbursement. Finally, she reports the latest thinking about the legal risks of communication and how to stay clear of trouble.

The Impact of Effective Communication

8

Make the time to put good communication techniques to work in your practice to enhance patient adherence, cost savings, and other benefits.

How to Build Rapport

24

Follow these tips to create connections with established as well as new patients.

Handling Difficult Encounters

36

Use strategies that can defuse these stressful situations.

Technology and Communication

58

Understand how to make the most of e-mail and e-visits while addressing potential problems.

The Legal Aspect of Communications

68

Learn how to prevent unintended, unauthorized disclosures in telephone and online communications.

For More Information

79